Eurofins Scientific stock trades at EUR 76.16 below yearly high

Eurofins Scientific stock stood at EUR 76.16 on Euronext Paris on September 24, 2026, 3.86 percent below its 52-week high of EUR 79.22. The price remains above the 52-week low of EUR 54.86, giving investors a clear measure of the stock's recent valuation range.

H1 earnings improve profitability

Eurofins reported 29 percent EPS growth in H1 2026, while adjusted EBITDA margin expanded by 130 basis points, according to the company's Eurofins investor update published on July 23, 2026. The combination matters because earnings advanced faster than the company's reported organic revenue growth of 2.7 percent in the first half.

The operating mix therefore remains the key financial signal. Revenue growth was modest, but the 130-basis-point margin expansion shows that cost control and portfolio actions contributed more to earnings than top-line acceleration in H1 2026.

2027 margin target sets the test

Eurofins' mid-term plan calls for an adjusted EBITDA margin of 24 percent in fiscal year 2027, long-term average growth of 6.5 percent per year, and cash conversion above 50 percent, the company said on its investor page. These targets give the market a measurable framework for judging whether the H1 profitability improvement can continue.

The valuation also leaves limited room for a purely defensive reading. Investing.com lists market capitalization at EUR 13.22 billion on September 24, 2026, and gives the next earnings date as November 2, 2026, in its company profile. That date creates the next scheduled checkpoint for margin delivery and cash generation.

Stock remains below yearly high

At EUR 76.16 on September 24, 2026, Eurofins Scientific stock was 3.86 percent below the 52-week high of EUR 79.22 and 38.96 percent above the 52-week low of EUR 54.86. The price position puts the upcoming November 2 earnings date alongside the 24 percent margin target as the clearest measurable reference points.